
    
      The study comprises four open-label substudies in patients with advanced urothelial cancer
      harboring FGFR GA who will be treated by single-agent derazantinib or derazantinib in
      combination with atezolizumab. The study enrolls patients with cisplatin-ineligible status,
      or patients whose disease progressed after either first-line treatment or prior treatment
      with FGFR inhibitors.
    
  